ANT 045
Alternative Names: ANT-045Latest Information Update: 27 Dec 2024
Price :
$50 *
At a glance
- Originator Antikor
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunoglobulin Fv fragments
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastric cancer; Solid tumours
Most Recent Events
- 23 Oct 2024 Pharmacodynamics, pharmacokinetics and safety data from preclinical studies in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
- 07 Jun 2021 Antikor files for patent protection for antibody fragments in United Kingdom (Antikor website, June 2021)
- 10 Apr 2021 Preclinical trials in Gastric cancer in United Kingdom (Parenteral)